Praluent Injection, Solution
Product Images NDC 61755-021

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Praluent (NDC 61755-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Regeneron Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (S Praluent 01)

A line graph depicting cumulative incidence of events over 48 months for PRALUENT (alirocumab) injection compared to placebo. The cumulative incidence is plotted on the vertical axis, time in months on the horizontal axis. PRALUENT shows a lower incidence curve than placebo, with hazard ratio 0.85 (95% CI 0.78 to 0.93). Numbers at risk for each group are shown below the timeline.*

FDA Label Image

Figure 2 (S Praluent 02)

A line graph showing LDL-C least squares mean percent change from baseline over 52 weeks comparing Praluent (alirocumab) versus placebo. The x-axis represents time in weeks, and the y-axis shows percent change in LDL-C. Praluent shows a marked reduction around -58% at 24 weeks and -52% at 52 weeks, while placebo remains near baseline with slight increases around 1% to 4%. The graph includes sample sizes for both groups at different time points.*

FDA Label Image

Figure 3 (S Praluent 03)

Line graph showing LDL-C least squares mean percent change from baseline over 52 weeks comparing Praluent (alirocumab) injection versus placebo. The x-axis shows time points in weeks, and the y-axis shows percent change, with Praluent demonstrating approximately a 46-47% decrease from baseline LDL-C and placebo showing around 7-8% increase. The graph includes subject numbers at various time points for both groups.*

FDA Label Image

Figure 4 (S Praluent 03a)

Line graph depicting LDL-C least squares mean percent change from baseline over 12 weeks for three groups: Placebo, Praluent 75 mg every 2 weeks, and Praluent 300 mg every 4 weeks. The y-axis shows LDL-C percent change, ranging from -90 to 40, and the x-axis shows time points in weeks from baseline to 12 weeks.*

FDA Label Image

S Praluent 03b

Line graph showing mean percent change in LDL-C from baseline over 12 weeks for Praluent 150 mg every two weeks versus placebo. Praluent group shows a decrease to about -27%, while placebo shows a slight increase to about 9%. Time points at baseline, 4, 8, and 12 weeks are displayed on the x-axis.*

FDA Label Image

Figure (S Praluent 04)

An instructional diagram of the Praluent (alirocumab) injection pen at 75 mg/mL strength. The image highlights key parts including the green button at the top, the main body labeled with product name and strength, a window, a yellow safety cover indicating the needle inside, and a blue cap at the bottom. It notes the pen is for single use only.*

FDA Label Image

Figure (S Praluent 05)

Label for Praluent 75 mg/mL injection, solution, a subcutaneous human prescription drug. The label shows the proprietary name Praluent and the active ingredient alirocumab with a strength of 75 mg/mL. The label is primarily white with blue and green color blocks and includes 'Rx ONLY.' Manufactured by Regeneron Pharmaceuticals, Inc.*

FDA Label Image

Figure (S Praluent 06)

An instructional diagram showing a close-up of a device window labeled 'A' with a green check mark, indicating the correct display or status of a component inside the device.*

FDA Label Image

Figure (S Praluent 07)

An instructional diagram showing a close-up of an injection pen highlighting the window that displays the medication level. A red X over the image indicates incorrect medication visibility or positioning, likely a warning not to use the pen in this state.*

FDA Label Image

Figure (S Praluent 08)

A circular timer illustration showing a partial yellow-orange fill representing a time duration of 30-40 minutes, indicated clearly within the filled area.*

FDA Label Image

Picture A (S Praluent 09)

An illustration showing recommended subcutaneous injection sites on a human body. Highlighted areas in orange include the outer upper arms, abdomen (excluding the area around the navel), and front of the thighs. The figure is depicted wearing blue undergarments with injection sites clearly marked for guidance.*

FDA Label Image

Figure B (S Praluent 10)

An instructional diagram showing a hand holding a blue cap and another hand holding an injection pen, indicating the removal of the blue cap from the pen. The illustration highlights the blue cap and uses an orange arrow to show the direction of cap removal.*

FDA Label Image

Figure (S Praluent 11)

An instructional illustration showing a hand holding an injection pen device, likely for subcutaneous administration. The pen has a green cap and white body with a yellow tip, consistent with a prefilled injection device for the drug Praluent (alirocumab). The image demonstrates how to hold the pen properly for use.*

FDA Label Image

Figure (S Praluent 12)

An instructional illustration showing how to properly hold a Praluent injection pen at a 90-degree angle for subcutaneous administration. A hand grips the pen vertically with an arrow indicating downward pressure. Inset images display a correct injection with a green check mark and an incorrect angle with a red X, emphasizing proper injection technique.*

FDA Label Image

Figure (S Praluent 13)

An instructional diagram demonstrating how to use the Praluent injection device. It shows a hand pressing down on the device with an arrow indicating downward pressure, followed by an arrow showing a twisting or rotating motion, accompanied by the instruction to 'Release the button immediately.' A 'click!' sound effect is depicted between the two actions.*

FDA Label Image

Figure (S Praluent 14)

An instructional illustration showing a hand holding a Praluent injection pen with the thumb pressing down on the pen's plunger. Adjacent to the hand is a timer graphic indicating 20 seconds, suggesting the duration for holding the injection in place after pressing.*

FDA Label Image

Figure (S Praluent 15)

An illustration showing a close-up view of the top part of a Praluent prefilled syringe barrel, highlighting the yellow interior solution through a transparent window. A callout bubble with the word 'click!' points to a small circular feature on the syringe, likely indicating a user interaction point on the device.*

FDA Label Image

Figure (S Praluent 16)

An instructional illustration showing a hand holding a Praluent injection pen against a forearm, indicating the subcutaneous injection administration with an upward orange arrow pointing to the skin area.*

FDA Label Image

Figure (S Praluent 17)

An instructional illustration showing a hand holding a Praluent injection pen above a sharps disposal container, with an orange arrow pointing downward indicating the pen is to be disposed of into the container. The injection pen is labeled with a visible dose indicator, and the image visually guides proper disposal of the subcutaneous injection device.*

FDA Label Image

Figure (S Praluent 18)

An illustrated diagram of a Praluent (alirocumab) injection pen labeled with 150 mg/mL strength. The diagram identifies key parts of the subcutaneous injection pen including the gray button, body, window, yellow safety cover indicating the needle inside, and blue cap. It notes that the device is for single use only.*

FDA Label Image

Figure (S Praluent 19)

Praluent 150 mg/mL injection, solution, subcutaneous use. The label shows the brand name Praluent with the active ingredient alirocumab clearly indicated. The concentration is 150 mg/mL, and the label is from Regeneron Pharmaceuticals, Inc. The text includes 'Rx ONLY' signifying prescription only status.*

FDA Label Image

Figure (S Praluent 20)

An instructional illustration showing a part of a cylindrical object, labeled with a letter A and highlighted within a blue circle, featuring a green check mark to indicate correct positioning or alignment.*

FDA Label Image

Figure (S Praluent 21)

An instructional diagram showing a close-up of a syringe window with yellow liquid inside, marked with a red X at the top right to indicate an incorrect condition or error related to the syringe content or appearance.*

FDA Label Image

Figure (S Praluent 22)

An infographic clock face highlighting a 30 to 40 minute time span, visually emphasizing the duration with a shaded orange segment covering about one-third of the clock.*

FDA Label Image

Picture A (S Praluent 23)

An illustration showing a front view of a human figure highlighting recommended subcutaneous injection sites for Praluent (alirocumab) injection, including the abdomen, upper arms, and front of the thighs, all marked in orange.*

FDA Label Image

Figure B (S Praluent 24)

An instructional illustration showing hands removing a blue cap from the end of a pen-like device, likely representing a step in preparing the Praluent injection pen for use.*

FDA Label Image

Figure (S Praluent 25)

Illustration of a hand holding a subcutaneous injection pen device, likely representing administration of Praluent (alirocumab) injection, solution. The device is held in a thumbs-up grip, suggesting proper handling for injection.*

FDA Label Image

Figure (S Praluent 26)

An instructional illustration showing a hand holding a Praluent injection pen for subcutaneous injection. The diagram emphasizes that the injection should be administered at a 90-degree angle to the skin, with a close-up comparison of correct and incorrect placement on the skin, marked respectively with a green check and red X.*

FDA Label Image

Figure (S Praluent 27)

An instructional illustration showing how to use the Praluent injection device. It depicts a hand pressing down on the injector button and releasing it immediately after hearing a 'click' sound, indicating proper activation of the device for subcutaneous administration.*

FDA Label Image

Figure (S Praluent 28)

An instructional illustration showing a hand holding a Praluent injection pen and pressing it against the skin, with an arrow pointing downward and a clock icon indicating to hold for 20 seconds. This depicts the subcutaneous injection technique for Praluent (alirocumab) injection, solution.*

FDA Label Image

Figure (S Praluent 29)

An instructional illustration showing a click indicator on a Praluent injection pen. The image highlights the action of a 'click' sound or mechanism, likely related to the preparation or use of the injection device for subcutaneous administration.*

FDA Label Image

Figure (S Praluent 30)

An instructional illustration showing a hand holding a Praluent (alirocumab) 150 mg/mL injectable pen vertically, with the yellow cap pointing downward. An orange arrow indicates the pen should be pressed down against the injection site, suggesting proper subcutaneous injection technique.*

FDA Label Image

Figure (S Praluent 31)

An instructional illustration showing a hand holding a Praluent injection pen inserted into the top of a vial. An orange downward arrow indicates the injection pen being pushed into the vial's cap, suggesting a step in the preparation or use of the injection solution.*

FDA Label Image

Principal Display Panel (75 mg/mL Pen Carton)

Praluent 75 mg/mL alirocumab injection, solution in a single-dose pre-filled pen carton. The label shows the product name, strength, dosage form for subcutaneous injection, and manufacturer Regeneron Pharmaceuticals, Inc. It includes usage and storage instructions, barcode, NDC 61755-020-01, and a visible image of the pre-filled pen inside the packaging.*

FDA Label Image

Principal Display Panel (150 mg/mL Pen Carton)

Praluent 150 mg/mL alirocumab injection label and carton packaging for one pre-filled pen. This subcutaneous injection solution is manufactured by Regeneron Pharmaceuticals, Inc. The label includes product name, strength, dosage form, single-dose usage, storage instructions, and barcode. The design features blue and white sections with the Regeneron logo and directions to open the package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.